Explaining risk factors for drug-resistant tuberculosis in England and Wales: Contribution of primary and secondary drug resistance

Epidemiology and Infection

Volumn 132, Issue 6, 2004, Pages 1099-1108

  Conaty, S J ^a   Hayward, A C ^a   Story, A ^b   Glynn, J R ^c   Drobniewski, F A ^b   Watson, J M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL TRANSMISSION; CHILD; CONTROLLED STUDY; ETHNOLOGY; FEMALE; GEOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SPUTUM SMEAR; TUBERCULOSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; EMIGRATION AND IMMIGRATION; ENGLAND; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; ISONIAZID; LONDON; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; TUBERCULOSIS, PULMONARY; WALES;

EID: 10444234292     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268804002869     Document Type: Article

References (33)

1. Anti-tuberculosis drug resistance in the world. Report no. 2: Prevalence and trends. WHO Global Tuberculosis Programme, Geneva, 2002.
2. Irish C, Herbert J, Bennett D, et al. Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6. Br Med J 1999; 318: 497-498.
3. Djuretic T, Herbert J, Drobniewski F, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax 2002; 57: 477-482.
4. White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000; 55: 962-963.
5. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. J Am Med Assoc 1994; 271: 665-671.
6. Schaberg T, Gloger G, Reichert B, Mauch H, Lode H. Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993. Eur Respir J 1995; 8: 278-284.
7. Weltman AC, Rose DN. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. Arch Intern Med 1994; 154: 2161-2167.
8. Bradford WZ, Martin JN, Reingold AL, Schecter GF, Hopewell PC, Small PM. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996; 348: 928-931.
9. Salomon N, Perlman DC, Friedmann P, Buchstein S, Kreiswirth BN, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 245-252.
10. Glynn JR, Jenkins PA, Fine PE, et al. Patterns of initial and acquired antituberculosis drug resistance in Karonga District, Malawi. Lancet 1995; 345: 907-910.
11. Riley LW, Arathoon E, Loverde VD. The epidemiologic patterns of drug-resistant Mycobacterium tuberculosis infections: a community-based study. Am Rev Resp Dis 1989; 139: 1282-1285.
12. Borchardt J, Kirsten D, Jorres R, Kroeger C, Magnussen H. Drug-resistant tuberculosis in northern Germany: a retrospective hospital-based study of 1,055 patients from 1984 until 1993. Eur Respir J 1995; 8: 1076-1083.
13. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. J Am Med Assoc 1997; 278: 833-837.
14. Granich RM, Moore M, Binkin NJ, Mcray E. Drug-resistant tuberculosis in foreign-born persons from Mexico, the Philippines, and Vietnam-United States, 1993-1997. Int J Tuberc Lung Dis 2001; 5: 53-58.
15. Hayward AC, Bennett DE, Herbert J. Risk factors for drug resistance in patients with tuberculosis in England and Wales [Abstract]. Thorax 1996; 51 (Suppl 3): S32.
16. Drobniewski FA, Magee JG, Smith EG, Williams R. PHLS mycobacteriology reference services in England and Wales. Commun Dis Rep CDR Review 1997; 7: R106-R109.
17. Rose AM, Watson JM, Graham C, et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 2001; 56: 173-179.
18. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity test in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
19. Collins CH, Grange JM, Yates MD. Tuberculosis bacteriology. In Organization and practice, 2nd edn. Oxford: Butterworth-Heinemann, 1997.
20. Murray CJL, Lopez AD. The global burden of disease. Cambridge, MA: Harvard University Press, 1996.
21. Stata [computer program], Version 7.0. Stata Corporation, Texas, USA, 2001.
22. Bowen EF, Rice PS, Cooke NT, Whitfield RJ, Rayner CF. HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet 2000; 356: 1488-1489.
23. Melzer M, Warley A, Milburn H, et al. Tuberculosis and HIV seroprevalence in Lambeth, Southwark and Lewisham, an area of South London. Respir Med 2003; 97: 167-172.
24. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.
25. de Viedma DG, Marin M, Hernangomez S, et al. Tuberculosis recurrences: reinfection plays a role in a population whose clinical/epidemiological characteristics do not favor reinfection. Arch Intern Med 2002; 162: 1873-1879.
26. Maguire H, Dale JW, McHugh TD, et al. Molecular epidemiology of tuberculosis in London 1995-7 showing low rate of active transmission. Thorax 2002; 57: 617-622.
27. Miller AB, Tall R, Fox W, Lefford MJ, Mitchison DA. Primary drug resistance in pulmonary tuberculosis in Great Britain: second national survey, 1963. Tubercle 1966; 47: 92-107.
28. Tuberculosis Section, Communicable Disease Surveillance Centre. Annual Report on Tuberculosis Cases Reported in 2000 in England, Wales and Northern Ireland, 2003.
29. Communicable Diseases Surveillance Centre. Drug resistant outbreak in North London - update. Commun Dis Rep CDR Wkly 2002; 12 31.
30. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
31. Communicable Diseases Surveillance Centre. Outbreak of hospital acquired multidrug resistant tuberculosis. Commun Dis Rep CDR Wkly 1995; 5: 161.
32. Breathnach AS, de Ruiter A, Holdsworth GM, et al. An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. J Hosp Infect 1998; 39: 111-117.
33. Salomon N, Perlman DC, DePalo VA, Kolokathis A, Wilets I. Drug-resistant tuberculosis: factors associated with rise in resistance in an HIV-infected urban population. Mt Sinai J Med 1994; 61: 341-348.